Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at Robert W. Baird increased their price target on the life sciences company's stock to $105.00.

Image of Cathie Wood via Wikimedia Commons. In a market dominated by headlines about artificial intelligence (AI), cloud ...

The market expects Illumina (ILMN) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is ...

Wall Street expects a year-over-year increase in earnings on higher revenues when CRISPR Therapeutics AG (CRSP) reports results for the quarter ended June 2025. While this widely-known consensus ...

Analysts William Tng and Tan Jie Hui believe Venture’s shares could find “support” at their FY2025 book value per share ...

Now that PacBio has broken through the $1 level that avoids Nasdaq delisting for now, we can focus on what might be ahead: ...

Detailed price information for Iqvia Holdings Inc (IQV-N) from The Globe and Mail including charting and trades.

Figma raised the proposed price range for its U.S. initial public offering on Monday and is now aiming for a valuation of $18 ...

Figma (FIG), a design software company that provides a wide range of artificial intelligence tools for creating and sharing ...

IBM's stock price is down today as the tech giant beat Wall Street expectations for revenue and profit, but missed on this ...

This AI giant dominates the market, and despite its explosive growth, the stock might be cheaper than you think.

Figma, which plans to sell nearly 12.5 million shares in the IPO, said it now expects a pricing of $30 to $32 a share, up from a previous estimate of $25 to $28 apiece. A pricing at the high end of ...